Some investors ask questions on the investor interaction platform: May I ask your company 1. Are there any products for the treatment of Helicobacter pylori? 2。 Has your innovative drug research and development been put on sale?
Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) (002317. SZ) said on the investor interaction platform on January 11 that the company’s omeprazole and antibiotic products (clarithromycin, tetracycline, etc.) belong to the treatment scheme of Helicobacter pylori. The company’s innovative drug project is currently in various stages of preclinical and clinical trials, and there are no products on the market for sale.
(source: Daily Economic News)
